Mafenide (INN; usually as mafenide acetate, trade name Sulfamylon) is a sulfonamide.
It is used to treat severe burns.[1][2]
Mafenide (Sulfamylon) can interfere with the kidney's role in hydrogen ion excretion, resulting in metabolic acidosis.
Mafenide is a topical sulfonamide used as adjunctive therapy of second- and third-degree burns. It is bacteriostatic against many gram-positive and gram-negative organisms including Pseudomonas aeruginosa. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could result in metabolic acidosis. This drug was approved by the FDA in 1948. Some sources state that mafenide is more appropriate for non-facial burns, while chloramphenicol/prednisolone or bacitracin are more appropriate for facial burns.[3]
[edit] Mechanism of Action
Mechanism of Action: Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns.
Contraindications/Precautions:Sulfonamide hypersensitivity; renal impairment.
[edit] Adverse Reactions
Superinfection, pain or burning upon application, rash, pruritus, tachypnea, hyperventilation, metabolic acidosis.
[edit] Drug interaction
Drug Interactions: No significant interactions
[edit] Dosage
For use adjunctive therapy of second- and third-degree burns to prevent infection: Topical dosage: Adults and children: Apply topically to a thickness of approximately 1.6 mm, to cleaned and debrided wound once or twice per day with a sterile gloved hand. Burned area should be covered with cream at all times.
[edit] See also
[edit] References
[edit] External links
Help
Add this page to your book
Show book (0 pages)
Suggest pages
(what is this?) (verify)
